Arietis
Arietis is developing first-in-class small molecule antibiotics to kill drug resistant bacterial pathogens and treat infections with a high unmet clinical need. Located at Boston University's Medical Campus, it focuses on innovative antimicrobial discovery and therapies for recalcitrant infections, utilizing proprietary antibiotics that activate the ClpP protease to rapidly kill resistant pathogens.
Industries
Nr. of Employees
small (1-50)
Products
ClpP-activating small-molecule antibiotic research program
Research program developing first‑in‑class small molecules that activate ClpP protease to kill drug‑resistant Gram‑positive pathogens and biofilm-associated bacteria; candidates progressed through in vitro screening, biophysical characterization, PK optimization, and in vivo efficacy models.
ClpP-activating small-molecule antibiotic research program
Research program developing first‑in‑class small molecules that activate ClpP protease to kill drug‑resistant Gram‑positive pathogens and biofilm-associated bacteria; candidates progressed through in vitro screening, biophysical characterization, PK optimization, and in vivo efficacy models.
Services
End-to-end preclinical programs to discover, optimize, and validate small‑molecule antibiotics, including medicinal chemistry, analytical characterization, in vitro screening, and in vivo efficacy testing.
Development and provision of biophysical and biochemical assays (SPR, ITC, NMR, protease activation) and a screening cascade for compound triage (MIC, protein binding, metabolic stability, solubility).
End-to-end preclinical programs to discover, optimize, and validate small‑molecule antibiotics, including medicinal chemistry, analytical characterization, in vitro screening, and in vivo efficacy testing.
Development and provision of biophysical and biochemical assays (SPR, ITC, NMR, protease activation) and a screening cascade for compound triage (MIC, protein binding, metabolic stability, solubility).
Expertise Areas
- Antimicrobial small-molecule discovery
- Medicinal chemistry and structure-guided optimization
- Preclinical PK/PD and resistance modeling
- Assay development for target activation and binding
Key Technologies
- ClpP protease activation
- Structure-guided drug design
- Peptide-bond forming synthetic chemistry
- Surface plasmon resonance (SPR)
News & Updates
A 2013 publication in Nature discusses how activated ClpP kills persisters and eradicates chronic biofilm infections.
A 2014 study in Antimicrobial Agents and Chemotherapy reports on the activity of HPi1 against Helicobacter pylori.
A 2013 article in Antimicrobial Agents Chemotherapy describes how azole antifungals are potentiated by 2-adamantanamine.
A 2013 review in Nature Reviews Drug Discovery discusses platforms for antibiotic discovery.
A 2013 publication in Nature discusses how activated ClpP kills persisters and eradicates chronic biofilm infections.
A 2014 study in Antimicrobial Agents and Chemotherapy reports on the activity of HPi1 against Helicobacter pylori.
A 2013 article in Antimicrobial Agents Chemotherapy describes how azole antifungals are potentiated by 2-adamantanamine.
A 2013 review in Nature Reviews Drug Discovery discusses platforms for antibiotic discovery.